Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telisotuzumab adizutecan - AbbVie

Next Previous
Drug Profile

Telisotuzumab adizutecan - AbbVie

Alternative Names: ABBV-400; Temab-A

Latest Information Update: 21 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II/III Adenocarcinoma; Non-small cell lung cancer
  • Phase II Solid tumours
  • No development reported Gastric cancer; Oesophageal cancer

Most Recent Events

  • 16 Sep 2026 AbbVie plans a phase III trial for Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) (IV) in January 2027 (NCT07821684)
  • 18 Aug 2026 AbbVie plans a phase II trial for Adenocarcinoma (Combination therapy) in Canada, China and USA (NCT07769502)
  • 06 Aug 2026 AbbVie plans a phase II trial for Squamous cell cancer (First-Line therapy, Recurrent, Metastatic disease, Combination therapy)(IV) in September 2026 (NCT07744126)(CTIS2025-524179-22-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top